At HAYA Therapeutics, we are pioneering a new class of programmable RNA-guided therapeutics that target the regulatory genome to reprogram disease-driving cell states. By decoding the causal biology of pathological cell states and the long-noncoding RNAs (lncRNAs) that regulate them, HAYA translates these insights into tractable therapeutic candidates designed to address disease at its source and restore cellular health. HAYA is advancing a broad pipeline of RNA-guided medicines for chronic, ag…